TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration

被引:63
|
作者
Gao, Ju [1 ]
Wang, Luwen [1 ]
Yan, Tingxiang [1 ]
Perry, George [2 ]
Wang, Xinglong [1 ]
机构
[1] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[2] Univ Texas San Antonio, Coll Sci, San Antonio, TX USA
基金
美国国家卫生研究院;
关键词
TDP-43; proteinopathy; Mitochondria; Neurodegeneration; Neurodegenerative diseases; Amyotrophic lateral sclerosis; Frontotemporal dementia; Alzheimer's disease; TAR-DNA-BINDING; AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; NUCLEAR FACTOR TDP-43; MESSENGER-RNA; PHASE-SEPARATION; ALZHEIMER-DISEASE; SPLICING REGULATION; TERMINAL FRAGMENTS; AXONAL-TRANSPORT;
D O I
10.1016/j.mcn.2019.103396
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Genetic mutations in TAR DNA-binding protein 43 (TDP-43) cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Importantly, TDP-43 proteinopathy, characterized by aberrant phosphorylation, ubiquitination, cleavage or nuclear depletion of TDP-43 in neurons and glial cells, is a common prominent pathological feature of various major neurodegenerative diseases including ALS, FTD, and Alzheimer's disease (AD). Although the pathomechanisms underlying TDP-43 proteinopathy remain elusive, pathologically relevant TDP-43 has been repeatedly shown to be present in either the inside or outside of mitochondria, and functionally involved in the regulation of mitochondrial morphology, trafficking, and function, suggesting mitochondria as likely targets of TDP-43 proteinopathy. In this review, we first describe the current knowledge of the association of TDP-43 with mitochondria. We then review in detail multiple mitochondrial pathways perturbed by pathological TDP-43, including mitochondrial fission and fusion dynamics, mitochondrial trafficking, bioenergetics, and mitochondrial quality control. Lastly, we briefly discuss how the study of TDP-43 proteinopathy and mitochondrial abnormalities may provide new avenues for neurodegeneration therapeutics.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The basis of clinicopathological heterogeneity in TDP-43 proteinopathy
    Kawakami, Ito
    Arai, Tetsuaki
    Hasegawa, Masato
    ACTA NEUROPATHOLOGICA, 2019, 138 (05) : 751 - 770
  • [22] Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes
    Prater, Katherine E.
    Latimer, Caitlin S.
    Jayadev, Suman
    GLIA, 2022, 70 (02) : 239 - 255
  • [23] Identification of TDP-43 modifying kinases in a C. elegans model of TDP-43 proteinopathy.
    Liachko, Nicole F.
    Guthrie, Chris R.
    Kraemer, Brian C.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2012, 33 : 31 - 32
  • [24] Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy
    Katsumata, Yuriko
    Abner, Erin L.
    Karanth, Shama
    Teylan, Merilee A.
    Mock, Charles N.
    Cykowski, Matthew D.
    Lee, Edward B.
    Boehme, Kevin L.
    Mukherjee, Shubhabrata
    Kauwe, John S. K.
    Kryscio, Richard J.
    Schmitt, Frederick A.
    Fardo, David W.
    Nelson, Peter T.
    ACTA NEUROPATHOLOGICA, 2020, 140 (05) : 659 - 674
  • [25] Neurodegeneration: A Leg Up on TDP-43
    Figley, Matthew D.
    Gitler, Aaron D.
    CURRENT BIOLOGY, 2015, 25 (16) : R728 - R731
  • [26] α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C-elegans model of TDP-43 proteinopathy
    Wong, Shi Quan
    Pontifex, Matthew G.
    Phelan, Marie M.
    Pidathala, Chandra
    Kraemer, Brian C.
    Barclay, Jeff W.
    Berry, Neil G.
    O'Neill, Paul M.
    Burgoyne, Robert D.
    Morgan, Alan
    NEUROBIOLOGY OF DISEASE, 2018, 118 : 40 - 54
  • [27] Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy
    Yuriko Katsumata
    Erin L. Abner
    Shama Karanth
    Merilee A. Teylan
    Charles N. Mock
    Matthew D. Cykowski
    Edward B. Lee
    Kevin L. Boehme
    Shubhabrata Mukherjee
    John S. K. Kauwe
    Richard J. Kryscio
    Frederick A. Schmitt
    David W. Fardo
    Peter T. Nelson
    Acta Neuropathologica, 2020, 140 : 659 - 674
  • [28] Perry's syndrome is a unique TDP-43 proteinopathy
    Wider, C.
    Dickson, D.
    Calne, D.
    Stoessl, J.
    Gutmann, L.
    Calne, S.
    Brown, L.
    Wszolek, Z.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S96 - S96
  • [29] ALS and FTLD: two faces of TDP-43 proteinopathy
    Liscic, R. M.
    Grinberg, L. T.
    Zidar, J.
    Gitcho, M. A.
    Cairns, N. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (08) : 772 - 780
  • [30] Significance and limitation of the pathological classification of TDP-43 proteinopathy
    Arai, Tetsuaki
    NEUROPATHOLOGY, 2014, 34 (06) : 578 - 588